24 Hrs
Source:
The Boston Globe
Researchers praise Trump’s fast-track plan
The article discusses the Trump administration's decision to expedite research and clinical testing of psychedelics, including psilocybin and ibogaine, for potential mental health treatments. Although these substances remain classified as Schedule 1 drugs, the move signals growing bipartisan interest and support for exploring their therapeutic benefits, particularly for conditions such as depression, PTSD, and addiction. Researchers are optimistic that increased funding and reduced regulatory barriers will accelerate the development of psychedelic-assisted therapies, with promising early results from trials involving cancer patients and veterans.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)